Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Obstetrics and Gynecology|May 2, 2007
Obstetric history and antibody titer in estimating severity of Kell alloimmunization in pregnancyD J van Wamelen, F J Klumper, M de Haas, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|December 15, 2015
Third trimester screening for alloimmunisation in Rhc-negative pregnant women: evaluation of the Dutch national screening programmeY M Slootweg, J M Koelewijn, I L van Kamp, et al.
Prenatal Diagnosis|May 1, 1993
A large retinoblastoma detected in a fetus at 21 weeks of gestationJ A Maat-Kievit, D Oepkes, N G Hartwig, et al.
American Journal of Obstetrics and Gynecology|September 25, 2001
The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatmentI L van Kamp, F J Klumper, R S Bakkum, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|February 8, 2022
Risk factors for RhD immunisation in a high coverage prevention programme of antenatal and postnatal RhIg: a nationwide cohort studyY M Slootweg, C Zwiers, J M Koelewijn, et al.
Vox Sanguinis|January 1, 1993
Evidence for the protective effect of maternal FcR-blocking IgG alloantibodies HLA-DR in Rh D-haemolytic disease of the newbornM C Dooren, I L van Kamp, H H Kanhai, et al.
Vox Sanguinis|January 1, 1990
Management of severe hemolytic disease with ultrasound-guided intravascular fetal transfusionsH H Kanhai, J Bennebroek Gravenhorst, I L van Kamp, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|April 5, 2013
Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestationI T M Lindenburg, I L van Kamp, E W van Zwet, et al.
Vox Sanguinis|January 1, 1994
No beneficial effect of low-dose fetal intravenous gammaglobulin administration in combination with intravascular transfusions in severe Rh D haemolytic diseaseM C Dooren, I L van Kamp, J W Scherpenisse, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|September 15, 2000
Benefits and risks of fetal red-cell transfusion after 32 weeks gestationF J Klumper, I L van Kamp, F P Vandenbussche, et al.
Pageof 3